Successful Management and Long-term Survival of Malignant Struma Ovarii with Radioactive Iodine Therapy.

Struma ovarii (SO) is a rare ovarian teratoma with predominant thyroid tissue. Malignant SO (MSO) occurs in 5%-10% of cases, with papillary and follicular thyroid carcinomas being the most common malignant types. The disease is typically diagnosed in women aged 40-60 years, and management protocols are not well defined due to its rarity.

Unexpectedly Low FDG and FAPI Uptake in Mucosal Melanoma: Case Report with Literature Review.

Mucosal melanomas (MMs) represent a rare subset of melanomas arising from melanocytes in noncutaneous sites such as mucosal membranes of the head-and-neck, gastrointestinal, and genitourinary tracts. Unlike cutaneous melanomas, MMs often present late due to their occult nature, leading to a poor prognosis. Fluorine-18 fludeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is widely utilized for staging and monitoring melanomas, leveraging their characteristic high FDG avidity.

Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.

Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.